Somagenetix
Z├╝rich
About Somagenetix
Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses. Somagenetix's mission is to use genetically modified phagocytes to treat patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $11.7M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2024)
- Website: somagenetix.com
- Phone: [email protected]
Industries & Categories
Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/somagenetix-70719 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.